United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,113,210.79. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Trading Up 0.2%

NASDAQ:UTHR traded up $1.30 during trading hours on Thursday, reaching $545.40. 395,406 shares of the company were exchanged, compared to its average volume of 479,446. The stock’s 50-day moving average is $568.19 and its 200-day moving average is $520.67. The firm has a market cap of $23.15 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company earned $6.63 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC boosted its position in shares of United Therapeutics by 2.8% in the 1st quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock worth $626,000 after buying an additional 29 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of United Therapeutics by 24.7% in the 1st quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after buying an additional 428 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares in the last quarter. Bull Harbor Capital LLC purchased a new stake in shares of United Therapeutics in the 1st quarter worth about $494,000. Finally, Strategic Investment Advisors MI boosted its position in shares of United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock worth $5,782,000 after buying an additional 1,662 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.